Nektar Therapeutics (NKTR) Shares Sold by SG Americas Securities LLC

SG Americas Securities LLC decreased its holdings in Nektar Therapeutics (NASDAQ:NKTR) by 10.4% in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 17,215 shares of the biopharmaceutical company’s stock after selling 1,994 shares during the quarter. SG Americas Securities LLC’s holdings in Nektar Therapeutics were worth $337,000 as of its most recent filing with the SEC.

Other large investors have also added to or reduced their stakes in the company. Arizona State Retirement System raised its position in Nektar Therapeutics by 1.0% in the second quarter. Arizona State Retirement System now owns 80,945 shares of the biopharmaceutical company’s stock worth $1,582,000 after acquiring an additional 800 shares in the last quarter. Prudential Financial Inc. raised its position in Nektar Therapeutics by 1.1% in the first quarter. Prudential Financial Inc. now owns 262,243 shares of the biopharmaceutical company’s stock worth $6,155,000 after acquiring an additional 2,890 shares in the last quarter. Elkfork Partners LLC raised its position in Nektar Therapeutics by 11.1% in the first quarter. Elkfork Partners LLC now owns 9,520 shares of the biopharmaceutical company’s stock worth $223,000 after acquiring an additional 952 shares in the last quarter. State of Wisconsin Investment Board purchased a new position in Nektar Therapeutics in the second quarter worth $2,248,000. Finally, Bank of Montreal Can raised its position in Nektar Therapeutics by 21.8% in the first quarter. Bank of Montreal Can now owns 8,195 shares of the biopharmaceutical company’s stock worth $192,000 after acquiring an additional 1,464 shares in the last quarter. Hedge funds and other institutional investors own 95.15% of the company’s stock.

Several research firms have issued reports on NKTR. Jefferies Group LLC reiterated a “buy” rating and issued a $23.00 price objective on shares of Nektar Therapeutics in a research report on Friday, July 21st. Roth Capital set a $33.00 price objective on Nektar Therapeutics and gave the stock a “buy” rating in a research report on Wednesday, August 9th. BidaskClub cut Nektar Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, August 4th. Evercore ISI began coverage on Nektar Therapeutics in a research report on Thursday, August 17th. They issued an “in-line” rating and a $20.00 price objective for the company. Finally, William Blair reiterated an “outperform” rating on shares of Nektar Therapeutics in a research report on Tuesday, July 18th. One research analyst has rated the stock with a sell rating, three have given a hold rating and nine have given a buy rating to the stock. Nektar Therapeutics has an average rating of “Buy” and an average target price of $26.10.

In other news, SVP Stephen K. Doberstein sold 1,701 shares of Nektar Therapeutics stock in a transaction on Wednesday, August 16th. The stock was sold at an average price of $19.32, for a total transaction of $32,863.32. Following the transaction, the senior vice president now owns 31,102 shares in the company, valued at $600,890.64. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, SVP Ivan P. Gergel sold 45,080 shares of Nektar Therapeutics stock in a transaction on Wednesday, July 12th. The shares were sold at an average price of $21.08, for a total value of $950,286.40. Following the transaction, the senior vice president now owns 51,961 shares in the company, valued at approximately $1,095,337.88. The disclosure for this sale can be found here. Insiders have sold 320,962 shares of company stock worth $6,615,210 over the last ninety days. 6.10% of the stock is owned by insiders.

TRADEMARK VIOLATION WARNING: This piece was originally reported by Chaffey Breeze and is owned by of Chaffey Breeze. If you are viewing this piece on another website, it was illegally stolen and reposted in violation of US & international trademark and copyright law. The correct version of this piece can be read at https://www.chaffeybreeze.com/2017/09/15/nektar-therapeutics-nktr-shares-sold-by-sg-americas-securities-llc.html.

Shares of Nektar Therapeutics (NASDAQ NKTR) opened at 22.00 on Friday. Nektar Therapeutics has a 12-month low of $11.41 and a 12-month high of $24.88. The firm’s market cap is $3.44 billion. The firm has a 50-day moving average price of $20.18 and a 200 day moving average price of $19.51.

Nektar Therapeutics (NASDAQ:NKTR) last posted its quarterly earnings data on Tuesday, August 8th. The biopharmaceutical company reported ($0.39) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.35) by ($0.04). Nektar Therapeutics had a negative return on equity of 1,223.34% and a negative net margin of 157.14%. The firm had revenue of $34.60 million during the quarter, compared to the consensus estimate of $33.64 million. During the same period in the prior year, the firm posted ($0.36) EPS. The firm’s quarterly revenue was up 5.5% on a year-over-year basis. On average, equities research analysts anticipate that Nektar Therapeutics will post ($0.94) earnings per share for the current fiscal year.

Nektar Therapeutics Profile

Nektar Therapeutics is a biopharmaceutical company that discovers and develops medicines in areas of high unmet medical need. The Company’s research and development pipeline of new investigational drugs includes treatments for cancer, auto-immune disease and chronic pain. It leverages its chemistry platform to discover and design new drug candidates.

Want to see what other hedge funds are holding NKTR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Nektar Therapeutics (NASDAQ:NKTR).

Institutional Ownership by Quarter for Nektar Therapeutics (NASDAQ:NKTR)

Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply